Del-1, an Endogenous Inhibitor of TGF-β Activation, Attenuates Fibrosis

Front Immunol. 2020 Feb 7:11:68. doi: 10.3389/fimmu.2020.00068. eCollection 2020.

Abstract

Uncontrolled activation of transforming growth factor (TGF)-β results in a wide range of pathologic conditions. Therapeutic interventions to regulate TGF-β signaling during fibrosis have been developed but the effectiveness is still limited. Here, we show that developmental endothelial locus-1 (Del-1) ameliorates fibrosis in mice by inhibiting αv integrin-mediated activation of TGF-β. Del-1 bound to αvβ6 integrin, an important activator of TGF-β, and inhibited the binding of αvβ6 integrin to the latency-associated peptide (LAP), thereby suppressing αv integrin-mediated activation of TGF-β. Lack of Del-1 increased colocalization of αv integrin and LAP in the lungs, which was reversed by Del-1 supplementation. The crucial role of Del-1 in regulating TGF-β activity was recapitulated in a mouse model of fibrosis using an adenovirus expressing inactive TGF-β1. Del-1 supplementation improved the pathological characteristics of the mice and reduced mortality. Thus, we propose that Del-1 is a negative regulator of TGF-β activation and a potential anti-fibrotic factor.

Keywords: Del-1 (developmental endothelial locus-1); fibrosis; inflammation; integrins; transforming growth factor-beta activation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Calcium-Binding Proteins / metabolism*
  • Cell Adhesion Molecules / metabolism*
  • Mice
  • Mice, Inbred C57BL
  • Pulmonary Fibrosis / metabolism*
  • Signal Transduction / physiology
  • Transforming Growth Factor beta / antagonists & inhibitors*

Substances

  • Calcium-Binding Proteins
  • Cell Adhesion Molecules
  • EDIL3 protein, human
  • Edil3 protein, mouse
  • Transforming Growth Factor beta